2011年2月,加拿大卫生部批准了Astellas制药公司的局部用钙调神经磷酸酶抑制剂他克莫司(tacrolimus)0.03%和0.1%油膏Protopic一新适应证,即以每周2次(如周一和周四各1次)患部涂敷方案分别用于免疫功能正常的2～15岁儿科和≥16岁青少年至成人中至重度特应性皮炎(常俗称为湿疹)患者的维持治疗,以预防疾病突发或延长到疾病突发的时间。 In February 2011, Health Canada approved Astellas Pharmaceuticals’s topical calcineurin inhibitor tacrolimus 0.03% and 0.1% ointment Protopic a new indication, that is, twice a week ( Such as once on Mondays and Thursdays) The affected area is used for the maintenance of patients with normal immune function in children aged 2-15 years and adolescents aged> 16 years to adults with moderate to severe atopic dermatitis (commonly known as eczema) To prevent the sudden onset of the disease or extend to the sudden onset of the disease.